Back

Effect of mavacamten on left ventricular myocardial volume, strain and tissue characteristics in patients with hypertrophic cardiomyopathy

1 September 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Management of hypertrophic obstructive cardiomyopathy Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Justin Tse

University of Calgary, Calgary (Canada)

6 More presentations in this session

Presentation thumbnail
Mavacamten in hypertrophic cardiomyopathy: use of accessible functional testing to examine real-world effectiveness
Doctor M. Todd (Belfast, GB)
Abstract Slides Video
Presentation thumbnail
Ablation scar at the his-bundle area predicts persistent complete atrioventricular block requiring pacemaker after alcohol septal ablation for obstructive hypertrophic cardiomyopathy
Doctor T. Kawai (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Hemodynamic and symptomatic response in real-world patients with hypertrophic obstructive cardiomyopathy and myosin inhibitor therapy
Mr A. Feidakis (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Real-world symptom and echocardiographic improvement in obstructive HCM patients treated with mavacamten: evidence of favorable disease modification
Doctor M. Desai (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Effect of Mavacamten on left ventricular diastolic function and left atrial function in obstructive hypertrophic cardiomyopathy
Doctor N. Cohen (Marseille, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Management of hypertrophic obstructive cardiomyopathy

The Event

Event poster

ESC Congress 2025

1 September 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Real-world symptom and echocardiographic improvement in obstructive HCM patients treated with mavacamten: evidence of favorable disease modification
thumbnail
Congress Presentation
Systematic evaluation of serial electrocardiographic changes in patients treated with mavacamten
thumbnail
Congress Presentation
Mavacamten treatment in obstructive hypertrophic cardiomyopathy for up to 30 weeks: An integrated analysis of cardiac magnetic resonance data from a diverse population in randomized clinical trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources